Inspire Investing LLC Lowers Stock Position in Precigen, Inc. $PGEN

Inspire Investing LLC cut its stake in shares of Precigen, Inc. (NASDAQ:PGEN) by 51.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 134,226 shares of the biotechnology company’s stock after selling 141,644 shares during the quarter. Inspire Investing LLC’s holdings in Precigen were worth $442,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in PGEN. Vontobel Holding Ltd. purchased a new stake in shares of Precigen during the 3rd quarter valued at $48,000. Voya Investment Management LLC raised its position in Precigen by 142.9% during the first quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 21,633 shares in the last quarter. Flower City Capital purchased a new stake in Precigen during the third quarter valued at about $66,000. BNP Paribas Financial Markets lifted its stake in Precigen by 134.7% during the second quarter. BNP Paribas Financial Markets now owns 48,803 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 28,005 shares during the last quarter. Finally, Strs Ohio purchased a new position in shares of Precigen in the 1st quarter worth about $70,000. Institutional investors own 33.51% of the company’s stock.

Insider Transactions at Precigen

In other Precigen news, Director Randal J. Kirk sold 1,900,036 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $4.18, for a total value of $7,942,150.48. Following the sale, the director owned 341,189 shares of the company’s stock, valued at $1,426,170.02. This trade represents a 84.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 4,866,329 shares of company stock valued at $20,233,899. 47.10% of the stock is owned by company insiders.

Precigen Price Performance

Shares of Precigen stock opened at $4.26 on Wednesday. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.04 and a quick ratio of 3.95. Precigen, Inc. has a one year low of $0.90 and a one year high of $5.22. The business’s 50 day simple moving average is $4.00 and its two-hundred day simple moving average is $3.20. The stock has a market capitalization of $1.51 billion, a P/E ratio of -3.06 and a beta of 1.16.

Precigen (NASDAQ:PGEN) last released its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). Precigen had a negative net margin of 3,912.92% and a positive return on equity of 1,066.10%. The company had revenue of $2.92 million for the quarter, compared to analysts’ expectations of $0.67 million. Analysts forecast that Precigen, Inc. will post -0.32 EPS for the current year.

Analyst Ratings Changes

PGEN has been the topic of a number of research reports. Wall Street Zen cut Precigen from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Wednesday, October 8th. Finally, HC Wainwright boosted their price objective on shares of Precigen from $8.50 to $9.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Precigen Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.